Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Failure Of J&J/Conor’s CoStar Stent Trial Sets Program Back Up To Four Years

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson's Conor Medsystems unit will discontinue development of its CoStar paclitaxel-eluting coronary stent and terminate sales of the device overseas following the failure of the firm's CoStar II U.S. pivotal study

You may also be interested in...



And Then There Were Three: J&J/Cordis Exits Drug-Eluting Stent Market

The first company to enter the drug-eluting stent market will now be the first to depart.

And Then There Were Three: J&J/Cordis Exits Drug-Eluting Stent Market

The first company to enter the drug-eluting stent market will now be the first to depart.

Angiotech and Conor settle

Angiotech reaches "favorable" agreement with Johnson & Johnson/Conor Medsystems Sept. 17 to settle all patent litigation ongoing since 2005 related to its paclitaxel-eluting stent technology. Angiotech licenses the patents in question exclusively to Boston Scientific for its Taxus stent. Johnson & Johnson discontinued development of the patent-relevant CoStar paclitaxel-eluting stent and terminated sales of the product overseas in May following disappointing trial results (1"The Gray Sheet" May 14, 2007, p. 9). The settlement covers all ongoing litigation in the UK, the Netherlands and Australia (2"The Gray Sheet" Jan. 22, 2007, p. 12)

Related Content

UsernamePublicRestriction

Register

MT024788

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel